Castle Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Castle Biosciences has a total shareholder equity of $391.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $453.3M and $62.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$243.10m |
| Equity | US$391.27m |
| Total liabilities | US$62.07m |
| Total assets | US$453.34m |
Recent financial health updates
Recent updates
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?
Aug 05Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)
Jun 06Financial Position Analysis
Short Term Liabilities: CSTL's short term assets ($295.6M) exceed its short term liabilities ($47.7M).
Long Term Liabilities: CSTL's short term assets ($295.6M) exceed its long term liabilities ($14.4M).
Debt to Equity History and Analysis
Debt Level: CSTL is debt free.
Reducing Debt: CSTL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CSTL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CSTL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.